Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 23
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Tipo de documento
Intervalo de ano de publicação
1.
J Oncol Pharm Pract ; 24(7): 550-552, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28714381

RESUMO

We report a case of a 51-year-old male with past medical history significant for cholangiocarcinoma presented with two weeks of worsening bilateral lower extremity swelling and erythema. Patient has been on active chemotherapy for his cholangiocarcinoma with Gemcitabine weekly infusions. Physical exam was significant for bilaterally petechial rash coalescing into ecchymoses over the dorsum of the feet, sparing soles and toes, which dissipated into thinning petechiae more proximally. On labs he did not have any leukocytosis, his platelet count was 50 × 103/µL and basic metabolic panel was benign. Patient was started on Vancomycin for presumed cellulitis. Lower extremity ultrasound Doppler ruled out deep venous thrombosis. Patient did have biopsies bilaterally on his legs, which showed hypersensitivity reaction consistent with the diagnosis of pseudocellulitis. His Vancomycin was discontinued and his symptoms improved. Our case further supports that pseudocellulitis is underrecognized and underreported, potentially leading to unnecessary antibiotic exposure and unnecessary diagnostic work-up as seen unfortunately in our patient. Unnecessary antibiotic exposure is increasing the risk for clostridium difficile and or antibiotic resistance, therefore awareness of this reaction is critical, as to avoid unnecessary antibiotics, and costly diagnostic workups.


Assuntos
Antimetabólitos Antineoplásicos/efeitos adversos , Celulite (Flegmão)/diagnóstico , Desoxicitidina/análogos & derivados , Antibacterianos/uso terapêutico , Antimetabólitos Antineoplásicos/administração & dosagem , Biópsia , Celulite (Flegmão)/induzido quimicamente , Desoxicitidina/administração & dosagem , Desoxicitidina/efeitos adversos , Eritema/diagnóstico , Humanos , Extremidade Inferior , Masculino , Pessoa de Meia-Idade , Gencitabina
2.
Am J Emerg Med ; 35(7): 1012, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28040387

RESUMO

51-year-old female who presented with progressive paresthesia, numbness of the lower extremities, double vision, and trouble walking. Physical exam was remarkable for areflexia, and ptosis. Her initial EKG showed nonspecific ST segment changes and her Troponin T was elevated to 0.41ng/mL which peaked at 0.66ng/mL. Echocardiogram showed a depressed left ventricular ejection fraction to 35% with severely hypokinetic anterior wall and left ventricular apex was severely hypokinetic. EMG nerve conduction study showed severely decreased conduction velocity and prolonged distal latency in all nerves consistent with demyelinating disease. She was treated with 5days of intravenous immunoglobulin therapy to which she showed significant improvement in strength in her lower extremities. Echocardiogram repeated 4days later showing an improved left ventricular ejection fraction of 55% and no left ventricular wall motion abnormalities. Takotsubo cardiomyopathy is a rare complication of Miller-Fisher syndrome and literature review did not reveal any cases. Miller-Fisher syndrome is an autoimmune process that affects the peripheral nervous system causing autonomic dysfunction which may involve the heart. Due to significant autonomic dysfunction in Miller-Fisher syndrome, it could lead to arrhythmias, blood pressure changes, acute coronary syndrome and myocarditis, Takotsubo cardiomyopathy can be difficult to distinguish. The treatment of Takotsubo cardiomyopathy is supportive with beta-blockers and angiotensin-converting enzyme inhibitors are recommended until left ventricle ejection fraction improvement. Takotsubo cardiomyopathy is a rare complication during the acute phase of Miller-Fisher syndrome and must be distinguished from autonomic dysfunction as both diagnoses have different approaches to treatment.


Assuntos
Antagonistas Adrenérgicos beta/uso terapêutico , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Síndrome de Miller Fisher/complicações , Cardiomiopatia de Takotsubo/etiologia , Ecocardiografia , Feminino , Humanos , Pessoa de Meia-Idade , Síndrome de Miller Fisher/fisiopatologia , Cardiomiopatia de Takotsubo/tratamento farmacológico , Cardiomiopatia de Takotsubo/fisiopatologia , Resultado do Tratamento , Função Ventricular Esquerda
3.
Am J Emerg Med ; 35(5): 800.e5-800.e6, 2017 May.
Artigo em Inglês | MEDLINE | ID: mdl-27865572

RESUMO

Authors and clinicians advocate lipase as the preferred serological test for the diagnosis for acute pancreatitis. While acute pancreatitis is among the differential diagnosis for elevated lipase levels, several other causes of elevated lipase levels have been identified including several reports Salmonella species as a causative agent. There also have been retrospective studies that have reported clinical pancreatitis associated with Salmonella infection. These studies concluded that clinical pancreatitis should be considered as a complication of Salmonella infections. However, Salmonella infections may induce elevated pancreatic enzyme levels without clinical pancreatitis or morphological pancreatic abnormalities through a variety of proposed mechanisms. The following is a case that describes a patient who developed Salmonella colitis and demonstrated elevated serum lipase levels without clinical pancreatitis.


Assuntos
Colite/sangue , Colite/microbiologia , Lipase/sangue , Infecções por Salmonella/sangue , Infecções por Salmonella/diagnóstico , Dor Abdominal/sangue , Dor Abdominal/diagnóstico por imagem , Dor Abdominal/microbiologia , Antibacterianos/uso terapêutico , Ciprofloxacina/uso terapêutico , Colite/diagnóstico , Colite/tratamento farmacológico , Diagnóstico Diferencial , Diarreia/sangue , Diarreia/diagnóstico por imagem , Diarreia/microbiologia , Humanos , Masculino , Pessoa de Meia-Idade , Náusea , Pancreatite , Radiografia Abdominal , Infecções por Salmonella/tratamento farmacológico , Infecções por Salmonella/microbiologia , Tomografia Computadorizada por Raios X , Resultado do Tratamento , Vômito
4.
Am J Emerg Med ; 35(8): 1214.e5-1214.e6, 2017 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-28539246

RESUMO

Lactic acidosis is a common metabolic acidosis characterized by increased serum lactate and is usually associated with a decreased blood pH. Lactic acidosis has many different causes but has been differentiated into type A, hypoxic causes, and type B, non-hypoxic causes. Tissue hypoxia, type A, is the most common cause, usually secondary to processes such as sepsis and multi-organ failure. Type A must be differentiated from type B in the correct clinical setting as treatments are vastly different. Type B causes may include drug side-effects, toxins, enzymatic defects, inherited or acquired, any of which may lead to overproduction or underutilization of lactate. However, as most clinicians are more familiar, and likely more initially concerned with hypoxic etiologies, evaluation is directed toward finding the source of hypoperfusion or hypoxia, and thus generally leading to a delay in discovering a type B cause (or mixed type A and type B). Here we describe a case of lactic acidosis in the setting of thiamine deficiency thought to be secondary to advanced lung cancer. The purpose of this paper is to bring awareness to the clinician to consider other causes of lactic acidosis when evaluating a patient.


Assuntos
Acidose Láctica/diagnóstico , Neoplasias Ósseas/tratamento farmacológico , Neoplasias Encefálicas/tratamento farmacológico , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Deficiência de Tiamina/complicações , Tiamina/uso terapêutico , Complexo Vitamínico B/uso terapêutico , Acidose Láctica/etiologia , Acidose Láctica/terapia , Idoso , Protocolos de Quimioterapia Combinada Antineoplásica , Neoplasias Ósseas/secundário , Neoplasias Encefálicas/secundário , Carboplatina/administração & dosagem , Confusão , Etoposídeo/administração & dosagem , Humanos , Masculino , Agitação Psicomotora , Resultado do Tratamento
13.
Proc (Bayl Univ Med Cent) ; 34(1): 169-171, 2020 Oct 16.
Artigo em Inglês | MEDLINE | ID: mdl-33456189

RESUMO

Worsening symptoms and fluid overload are the hallmarks of heart failure (HF) decompensation, and fluid removal is central to improvement. Despite high-dose loop diuretics, patients with decompensated HF may develop suboptimal diuresis/diuretic resistance. Sequential nephron blockade with a combination of loop and thiazide/thiazide-like diuretics may be insufficient, resulting in poor outcomes. We present a case wherein urine output improved significantly with acetazolamide. Although the diuretic capacity of acetazolamide is weak on its own, it might be efficient in aiding the efficacy of loop diuretics. We discuss the pathophysiological basis and evidence behind its potential role in diuretic resistance. Drawing from current understanding, we propose a stepwise approach to diuresis in such patients.

14.
Proc (Bayl Univ Med Cent) ; 30(4): 410-412, 2017 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-28966446

RESUMO

To prevent recurrence of acute coronary syndrome (ACS), national practice guidelines recommend use of five-drug combination therapy. Our study assessed the proportion of patients discharged on all five medications following ACS and determined reasons for nonadherence. A retrospective, single-center chart review was conducted at a tertiary academic medical center. Patients 18 years and older who were admitted to the cardiac care unit with a diagnosis of ACS between January 2013 and January 2015 were included. Overall, 200 patients were screened and 155 were included in the study. Half of the patients received all guideline-recommended classes of pharmacological agents at discharge. The other half-78 patients-did not receive the five-drug combination, of whom 48 (62%) had reasons documented for nonadherence. Our study's findings suggest that rates of adherence need to improve given the clear benefits of these medications.

15.
Proc (Bayl Univ Med Cent) ; 30(3): 307-308, 2017 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-28670066

RESUMO

A 70-year-old woman presented with progressive lower extremity weakness and heaviness accompanied with chest pain. Troponin T was elevated, and an echocardiogram showed a left ventricular ejection fraction of 30% and a hypokinetic left ventricular apex. Neurophysiologic testing was consistent with Guillain-Barré syndrome, which was treated with intravenous immunoglobulin therapy. Repeat echocardiogram showed an improved left ventricular ejection fraction and no left ventricular wall motion abnormalities. Takotsubo cardiomyopathy is a rare complication of Guillain-Barré syndrome; less than 10 cases have been reported.

16.
J Basic Clin Pharm ; 8(1): 40-41, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28104974

RESUMO

A 76-year-old female, with medical history significant for systolic congestive heart failure, who presented to the emergency department with lethargy and abdominal pain with diarrhea for the past 3 weeks. Due to hypotension, the patient received multiple boluses of isotonic saline and was started on norepinephrine. Laboratories were significant for severe digoxin toxicity (29 ng/mL), in setting of acute kidney injury. Electrocardiogram (EKG) revealed a new right bundle branch block (RBBB). She was given Digibind and her repeat digoxin level was 20 ng/mL. Repeat EKG showed resolved RBBB. This case identifies that patients with digoxin toxicity are at risk for RBBB. This is a rare finding and is not commonly recognized. Emergency medicine physicians are often the first to encounter patients with digoxin toxicity and need to be aware of such EKG findings.

17.
Nat Rev Drug Discov ; 13(11): 787-8, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-25359361

RESUMO

TransCelerate BioPharma was formed in 2012 as a non-profit organization with a mission to collaborate across the biopharmaceutical research and development community to identify, prioritize, design and facilitate the implementation of solutions to drive efficient, effective and high-quality delivery of new medicines.


Assuntos
Comportamento Cooperativo , Descoberta de Drogas/métodos , Organizações sem Fins Lucrativos , Academias e Institutos , Ensaios Clínicos como Assunto , Agências de Assistência Domiciliar , Humanos , Estados Unidos , United States Food and Drug Administration
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA